ESMO Open
Издатель: Elsevier · ISSN 2059-7029 · 38 статей
-
Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: phase II single-arm trial (CIPHER)
Publication date: Available online 23 September 2026 Source: ESMO Open Author(s): R. Jain, N. Vasudeva, H. Baskarane, A. Arora, A. Sharma, A. Kumar, K.P. Haresh, S. Kaushal, S.A. Shamim, B. Nayak, R.K. Sahoo, M. Divakar, A. Seth, A....
-
Response to Letter to the Editor: “NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial”
Publication date: Available online 7 October 2026 Source: ESMO Open Author(s): T. Kahl, S.D. Eisenring, G. Liposits
-
Letter to the Editor: further reply to Kahl et al. regarding ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’
Publication date: Available online 9 October 2026 Source: ESMO Open Author(s): T. Macarulla, R. Pazo Cid, M.S. Womack, A. Cubillo Gracian, A. Zervoudakis, H. Hatoum, V. Chung, A. Patel, A.S. Paulson, S. Pant, E.M. O’Reilly, R.A. Hubner,...
-
Liquid biopsy-guided molecular hyperselection for anti-EGFR rechallenge therapy in refractory metastatic colorectal cancer: a pooled analysis of four trials☆
Publication date: Available online 25 October 2026 Source: ESMO Open Author(s): D. Ciardiello, L. Boscolo-Bielo, C.M. Parseghian, A. Sartore-Bianchi, F. Pietrantonio, G. Martini, G. Mauri, G. Vetere, A. Avallone, A. De Stefano, S....
-
The cost of intensification in high-risk non–muscle-invasive bladder cancer
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): M. Zugman, I. Kirche Duarte, W. Baccaglini
-
Structured physical activity in high-risk stage II and stage III colon cancer: tertiary prevention of colorectal cancer recurrence or primary prevention in a population at high risk of secondary cancers?
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): R. Moretto, V. Conca, E. Blondeaux, C. Cremolini
-
Adjuvant therapy for RCC: considerations beyond survival metrics
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): R.A. Fribourg-Liendo, W. Yip
-
Letter re: ELECLA trial: final results of perioperative chemotherapy with fluoropyrimidine and oxaliplatin in mismatch repair proficient locally advanced colon cancer
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): G. Turri, C. Pedrazzani
-
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early and locally advanced non-small-cell lung cancer
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): H. Hayashi, A. Zer, H. Kenmotsu, M. Tachihara, J. Cui, N. Sutandyo, N. Lokeshwar, G.-W. Lee, P.-J. Voon, K. Samala, M.-K. Ang, C.-H. Chiu, V. Sriuranpong,...
-
ESMO and ASCO Consensus on Good Clinical Practice Guideline E6(R3): A Step Forward Towards Streamlining Clinical Research
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): J.L. Perez-Gracia, L. Levit, M.F. Sanmamed, P. Sharma, F. André, C. Hosius, B. Patel, A. Nuti, L. Carey, T. Amaral
-
Parity, breastfeeding, and reproductive timing are associated with tumour-infiltrating lymphocytes in hormone receptor-negative breast cancer: a population-based cohort study
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): E. Gabrielsen, A. Wirsing, T. Wilsgaard, I. Thune, H. Frydenberg, T. Lofterød, E. Mortensen, H. Nalwoga, L.A. Akslen, H.S. Haugnes, E.S. Blix
-
Germline pharmacogenetic variants associated with trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer: PROCURE project
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): A. Arenas, C. Saura, M. Alva-Bianchi, J. de Nicolás-Hernández, M. Gion, J.M. Cejalvo, E. Llabrés, J. Cortés, A. Falcón, S. Pernas, A. López de Sa, M....
-
Patterns of central nervous system and leptomeningeal involvement in advanced breast cancer with invasive lobular histology: a large multicenter study with a focus on estrogen receptor-positive/HER2-negative disease
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): F. Miglietta, C. Vernieri, T. Giarratano, G. Griguolo, M. Bottosso, A. Vingiani, F. Piacentini, M. Cacciatore, A. Botticelli, G. Fotia, P. Napolitano, G....
-
Variation in baseline estrogen levels, menopause-related adverse events and early study discontinuation among women on the placebo-controlled MAP.3 exemestane prevention trial
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): V. Ho, R. Pasquet, R.J. Singh, M.P. Goetz, D. Tu, J.N. Ingle, H. Richardson, Hugh M.C. Scarth, Louise Provencher, Pierre Dube, Marie-Helen Mayrand, Edgard...
-
Ultra-sensitive MRD assessment in long-term complete responders to anti-HER2 therapy in HER2-positive metastatic breast cancer: initial results from HER2-CR study☆
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): K. Nozawa, Y. Ozaki, H. Kotani, Y. Akita, A. Kataoka, A. Yoshimura, K. Yukino, K. Nonogaki, T. Takano, T. Ueno, Y. Wanifuchi-Endo, T. Asano, N. Horisawa,...
-
A randomized, placebo-controlled, phase II study of docetaxel and platinum with or without erlotinib in recurrent/metastatic head and neck squamous-cell carcinomas
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): W.N. William, L. Feng, M.S. Kies, S. Ahmed, G.R. Blumenschein, B.S. Glisson, E. Massarelli, F.M. Johnson, C. Lu, X. Le, L.P. Kowalski, E.S. Kim
-
Efficacy of immediate radiotherapy versus salvage radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma responsive to chemoimmunotherapy
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): Q.-T. Zhang, J.-R. He, H.-B. Guo, Y.-N. Sun, J. Chen, H. Cheng, Y.-X. Xiao, X.-S. Sun, L.-F. Wu, X.-Y. Li, Q.-Y. Chen, L.-Q. Tang, H.-Q. Mai, L.-T. Liu
-
Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter study
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): S. Kobayashi, T. Takamoto, A. Shiomi, A. Takahashi, M. Shiozawa, H. Taniguchi, Y. Nishizawa, D. Nobuoka, S. Yasuta, T. Kato, K. Ando, A. Taketomi, Y....
-
Estimating the clinical benefit of metastases resection in liver-limited metastatic colorectal cancer: an IPD-based pooled analysis of nine randomized trials☆
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): M.M. Germani, A. Taravella, D. Rossini, L. Weiss, F. Morano, F. Bergamo, V. Studiale, A. Stahler, M. Carullo, L. Salvatore, K. Heinrich, A. Passardi, D.P....
-
Pembrolizumab plus FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: analysis of the FLOT cohort from the phase 3 KEYNOTE-585 study
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): S.-E. Al-Batran, K. Shitara, G. Folprecht, M. Moehler, E. Goekkurt, I. Ben-Aharon, S. Lonardi, S. Stein, A. Hubert, I. Chau, M. Mishaeli, L. Villanueva,...
-
A phase I/II study using cabozantinib and lanreotide as treatments for advanced GEP-NETs for which molecular targeted therapy or chemotherapy have failed (SCALET): TCOG T2221 study☆
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): H.-J. Tsai, M.-H. Chen, C.-F. Hsiao, L.-Y. Bai, Y.-Y. Chen, W.-C. Chou, Y.-Y. Su, M.-S. Dai, Y.-H. Liang, Y.-S. Shan, C.-J. Yen, T.-H. Liu, J.-H. Chen,...
-
Nivolumab and total neoadjuvant treatment for locally advanced rectal cancer: results of a phase II trial (CA209-8M4)
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): B. Brenner, G. Perl, A. Rosenberg-Ayal, M. Cohavi, A. Sulkes, Z. Cohen, H. Bernstine, D. Varon, A. Levy-Barda, S. Morgenstern, I. White, N. Gurevich, Y....
-
daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): S. Paulson, M. Ikeda, L. Shen, A. Stein, T. Macarulla, M. Milella, T. Golan, Z. Wainberg, J. Taieb, L. Wang, F. Polydoros, C. Abecunas, E. López, E.M. O’Reilly
-
Real-world adoption of circulating tumor DNA testing and adjuvant treatment decisions after radical cystectomy for muscle-invasive bladder cancer
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): H.K. Litt, A. Sahni, G. Mo, K. Patel, M. Donovan, R.D. Chow, R. Mamtani
-
Identification and prognostic value of non-hotspot POLE exonuclease domain mutations in endometrial cancer
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): T. Kawai, H. Yoshida, M. Kobayashi Kato, M. Yamaguchi, T. Shiraishi, H. Okada, T. Kondo, T. Koyama, D. Higuchi, T. Harazawa, A. Ikki, T. Yamanaka, A....
-
Prognostic value of PD-L1 expression and association with HRD in high-grade serous ovarian cancer: an ancillary analysis of the PAOLA-1/ENGOT-ov25 trial (GINECO)
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): G. Bataillon, S. Cyrille, A. Salvioni, A. Trecourt, C. Jeanne, C. Genestie, I. Ray-Coquard, E. Pujade-Lauraine, R. De Cecio, U. Canzler, C. Zamagni, P....
-
Mapping off-label use and reimbursement pathways for oncology drugs in The Netherlands: a cross-sectional observational study
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): H. Timmer, A.H. Huisman, H. Gelderblom, S. Barjesteh van Waalwijk van Doorn-Khosrovani
-
Nivolumab in patients with advanced solid tumors with ctDNA-defined high blood tumor mutational burden: a phase II trial
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): Y. Nakamura, T. Esaki, T. Nishina, E. Shinozaki, H. Taniguchi, T. Kato, Y. Komatsu, S. Yuki, K. Kato, M. Wakabayashi, T. Ikeno, Y. Ishiguro, K. Takahashi,...
-
Genomic landscape of ERBB3 alterations in metastatic solid tumours: a real-world data analysis
Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): M. Kwon, Y. Go, J.E. Shin, S.H. Lim, J.Y. Hong, S.H. Park, J.O. Park, J. Lee, S.Y. Ha, S.T. Kim
-
Rethinking cardiac monitoring in patients receiving trastuzumab-based HER2-directed therapies for breast cancer: a meta-analysis and cost-effectiveness analysis
Publication date: December 2026 Source: ESMO Open, Volume 11, Issue 12 Author(s): M.C. Saad Menezes, A. Barac, J.N. Upshaw, N.U. Lin, J.B. Rabinowitz, A. DeMichele, S.A. Hurvitz, E.A. Perez, J.H. Schwartz, A. Julian, V. Mico, S....